Translocation renal cell carcinoma, disproportionately affecting children and young adults, has long eluded effective treatment, partly due to the complexity of its driving genetic alterations. At the heart of this malignancy lie TFE3 oncofusions—recombinant proteins produced from chromosomal rearrangements that forcibly bind together segments of DNA that should remain separate. Understanding how these fusion proteins commandeer the cellular machinery has been a formidable challenge. The Texas A&M team’s research reveals that these oncofusions co-opt RNA molecules not merely as conveyers of genetic instructions but as architects constructing dynamic liquid-like droplets within the cell nucleus. These condensates act as transcriptional hotspots, intensifying the expression of genes that fuel tumor growth.

Contrary to the longstanding view of RNA as merely passive messengers transferring genetic data from DNA to proteins, the study illuminates RNA’s role as an active engineering scaffold within cancer cells. By assembling intricate, phase-separated condensates, RNA creates concentrated environments that aggregate fusion proteins and co-factors into transcriptional hubs. These structures augment the ability of TFE3 oncofusions to activate oncogenic gene expression, effectively transforming the nuclear landscape into a playground for unchecked proliferation. The team’s investigation further identifies PSPC1, an RNA-binding protein, as a formidable stabilizer that reinforces the structural integrity and functionality of these droplets, amplifying their pathological impact.

Elucidating these processes required harnessing a suite of state-of-the-art molecular techniques. CRISPR gene editing allowed precise tagging of the TFE3 oncofusion proteins in patient-derived cell lines, enabling high-resolution tracking of their spatial distribution within the nucleus. The employment of SLAM-seq, a cutting-edge sequencing methodology, provided temporal snapshots of nascent RNA synthesis dynamics, revealing shifts in gene activation patterns coinciding with droplet formation. Complementary approaches such as CUT&Tag and RIP-seq were instrumental in mapping the binding sites of fusion proteins on chromatin and RNA substrates, respectively, delineating the molecular geography of these transcriptional hubs. Proteomics analysis further enriched the picture, pinpointing key protein constituents, most notably PSPC1, that orchestrate condensate stabilization.

While illuminating the mechanism was a monumental achievement, the researchers boldly pressed on to test the vulnerability of these droplets. To translate their insight into therapeutic potential, they engineered a sophisticated chemogenetic system leveraging nanobody technology. Nanobodies, compact antibody fragments, were fused to a specialized dissolver protein designed to selectively dismantle these condensates. Upon chemical activation, the nanobody locks onto the TFE3 fusion proteins, instigating the dispersal of the liquid-like hubs. This molecular switch wielded remarkable efficacy, halting proliferation in cultured cancer cells and significantly curbing tumor growth in mouse models. Such a strategy signals a transformative approach to an aggressive pediatric cancer currently devoid of targeted treatments.

The potential implications of these findings extend well beyond tRCC. Fusion proteins are notorious culprits across various pediatric malignancies, notoriously difficult to target with conventional therapeutics. The discovery of RNA-mediated phase-separated condensates as critical enablers of oncogenic transcription opens a novel frontier for therapeutic intervention. By selectively disrupting these liquid droplet hubs, scientists may be able to dismantle the very platforms that consolidate oncogenic signals, effectively “cutting the power” to the cancer’s growth machinery. This represents a paradigm shift, focusing on the emergent properties of molecular assemblies rather than individual protein targets.

This work underscores the nuanced complexity of cancer cell biology, where the cellular environment and molecular interactions are as vital as the genetic mutations themselves. It challenges the traditional dogma that RNA functions solely as an ephemeral intermediate, exposing its architectural capabilities in pathological states. The strategic targeting of condensate formation Poignantly embodies the promise of precision medicine, aiming to intervene at the molecular nexus of cancer cell survival while minimizing collateral damage to normal tissues. Such precision is crucial in pediatric settings, where long-term side effects of therapy can significantly impact quality of life.

Moreover, the multidisciplinary approach employed by the Texas A&M team exemplifies the power of contemporary biomedical research, fusing gene editing, novel sequencing, chromatin profiling, and proteomic techniques into a cohesive investigative framework. This convergent strategy enabled the researchers to dissect the condensate biology at an unprecedented depth, building a comprehensive model that integrates structural, functional, and therapeutic dimensions. The ability to visualize, mechanistically explore, and then chemically control these RNA-protein assemblies heralds an exciting era of targeted cancer treatments.

The central role of PSPC1 as a droplet stabilizer enriches the mechanistic insights and presents an additional therapeutic target. By modulating proteins that buttress the condensates, future interventions could employ dual strategies—disrupting both scaffold RNA and stabilizer proteins to maximize the collapse of oncogenic hubs. Such combinatorial approaches could enhance the robustness and durability of therapeutic responses, potentially overcoming resistance mechanisms that often plague monotherapies.

Acknowledging the formidable clinical challenge posed by tRCC, which accounts for nearly a third of renal cancers in younger populations, this research represents a beacon of hope. It translates fundamental discoveries into actionable strategies, potentially paving the way for safer and more effective treatments tailored to the unique biology of pediatric cancers. The precision with which these condensates can now be pinpointed and manipulated also invites broader applications in oncology, particularly in cancers where aberrant gene fusions redefine cellular identity and behavior.

The collaborative efforts of molecular biologists, geneticists, structural biologists, and translational researchers at Texas A&M Health highlight the interdisciplinary nature of modern cancer research. Their work not only deciphers the complex “condensate code” exploited by tumors but also charts a blueprint for innovative drug design in an era hungry for breakthroughs beyond traditional chemotherapy and targeted kinase inhibitors. As the field advances, the study’s findings may catalyze the development of condensate-targeting drugs, nanobody therapies, and chemogenetic tools—creating a new arsenal against cancers driven by elusive fusion proteins.

Ultimately, the discovery redefines the conceptual framework of cancer pathogenesis, emphasizing how RNA’s role transcends classical functions and participates actively in the spatial organization of gene regulation. By exposing and then toggling off the molecular switches that sustain cancerous growth hubs, the Texas A&M research not only unravels fundamental biological secrets but lights a path toward transforming clinical outcomes in a devastating, previously intractable disease.

Subject of Research: Translocation renal cell carcinoma (tRCC) and RNA-mediated oncogenic condensates

Article Title: RNA-mediated condensation of TFE3 oncofusions facilitates transcriptional hub formation to promote translocation renal cell carcinoma

News Publication Date: 30-Sep-2025

Web References:

• Texas A&M Health: https://health.tamu.edu/
• Original Study DOI: http://dx.doi.org/10.1038/s41467-025-63761-z

References:

• Study published in Nature Communications, DOI 10.1038/s41467-025-63761-z

Keywords:
Cancer research, Tumor microenvironments, Cancer cells, Oncology, Signal transduction, Extracellular spaces, Cancer treatments, Biomedical engineering, Diseases and disorders, Health and medicine, Translational research, Clinical medicine, Drug delivery systems

The Legion of Honor, one of France’s highest accolades, acknowledges individuals whose work has significantly advanced science and society. Dr. Merad’s selection reflects her visionary research elucidating the complex roles of innate immune cells in tumor microenvironments and chronic inflammatory states. Her contributions have not only deepened fundamental understanding but have also shepherded innovative therapeutic strategies that harness the immune system against malignancies.

At the Icahn School of Medicine at Mount Sinai, Dr. Merad holds the Mount Sinai Professorship in Cancer Immunology, alongside numerous leadership posts. She is the Founding Chair of the Department of Immunology and Immunotherapy, Director of the Marc and Jennifer Lipschultz Precision Immunology Institute, and oversees the Human Immune Monitoring Center. In 2024, she assumed the role of Dean for Translational Research and Therapeutic Innovation, enabling her to accelerate early-phase clinical trials and foster collaborations bridging academic discovery with pharmaceutical development.

Ambassador Laurent Bili praised Dr. Merad’s tireless efforts to fortify Franco-American scientific partnerships, highlighting her career as an exemplar of achievement in the biomedical sciences. The ambassador specifically referenced her critical involvement in the Mount Sinai COVID-19 Biobank, a comprehensive resource that enabled granular analysis of immune responses to SARS-CoV-2, underpinning therapeutic advances during the pandemic.

Dr. Merad’s groundbreaking work has been pivotal in identifying tissue-resident macrophages—specialized innate immune cells residing within organs that orchestrate tissue homeostasis, repair, and inflammatory responses. Her seminal 2010 publication in Science laid the foundation for this field, redefining macrophage ontogeny and functional heterogeneity. This research reshaped immunology by delineating how resident macrophages contribute to disease pathogenesis and tissue regeneration, insights that continue to influence new therapeutic approaches.

Building upon this foundation, Dr. Merad has uncovered novel immunomodulatory targets capable of enhancing anti-tumor immunity. Her recent investigations, disclosed in Nature, demonstrate the clinical efficacy of strategies modulating macrophage function to improve outcomes in lung cancer patients. These findings illuminate previously unrecognized mechanisms by which innate immune cells can be leveraged to potentiate cancer immunotherapy, promising significant advances in treatment paradigms.

Beyond her scientific discoveries, Dr. Merad is renowned for her mentorship, cultivating the next generation of translational and clinical researchers. She credits Mount Sinai’s dynamic and innovation-driven environment for propelling her own research trajectory. “Mount Sinai offers unparalleled resources and collaborative networks for early innovators aiming to transform scientific insights into therapies,” she noted.

Born in Paris and raised in Algiers within a family steeped in medicine and science, Dr. Merad’s interdisciplinary education spans continents. Her medical degree was earned at the University of Algiers, followed by hematology/oncology residency training in Paris. She completed her PhD in Immunology through a distinguished joint program between Stanford University and the University of Paris, reflecting a bicontinental scholarly foundation.

Her remarkable career achievements are recognized by election to the U.S. National Academy of Sciences and the National Academy of Medicine, two of the highest honors in the life sciences. Dr. Merad’s accolades also include fellowship in the American Association for Cancer Research and the Academy of Immuno-Oncology, alongside prestigious awards such as the INSERM International Prize and the Sjöberg Prize from the Royal Swedish Academy of Sciences, affirming her global leadership in immunology and oncology.

Reflecting on receiving the Legion of Honor, Dr. Merad expressed profound gratitude and humility. “This recognition honors not only my personal scientific journey but also the collective spirit of collaboration and support intrinsic to my time at Mount Sinai,” she said. Her statement underscores the interdependence of individual achievement and institutional ecosystems in advancing biomedical frontiers.

Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean at the Icahn School of Medicine at Mount Sinai, lauded Dr. Merad’s seminal discoveries and leadership, emphasizing their broad impact on global health. “Her trailblazing research has reshaped our understanding of immune mechanisms and opened new therapeutic frontiers,” Dr. Charney remarked, “We are immensely proud to see her recognized with France’s highest civilian distinction, a testament to her exceptional scientific vision and dedication.”

The Icahn School of Medicine at Mount Sinai remains a world leader in biomedical research and education, hosting thousands of scientists and clinicians committed to translational medicine. Under leaders like Dr. Merad, the institution continues to push the boundaries of immunology, oncology, and precision therapeutics, driving innovations that will transform patient care worldwide.

Subject of Research: Immunology, macrophage biology, cancer immunotherapy, innate immune response, translational research

Article Title: Miriam Merad Receives France’s Prestigious Legion of Honor for Pioneering Immunology and Cancer Research

News Publication Date: May 20, 2025

Web References:

• https://profiles.mountsinai.org/miriam-merad
• https://icahn.mssm.edu/research/immunology
• https://labs.icahn.mssm.edu/minervalab/resources/data-ark/mscic-covid-19-biobank/

Image Credits: Mount Sinai Health System

Keywords: Innate immune response, macrophage biology, cancer immunology, translational research, precision medicine, immune monitoring, COVID-19 Biobank, tissue-resident macrophages, immunotherapy, scientific collaboration